UPDATED: Patheon soars in its last year as a public CMO

Contract manufacturer Patheon boosted its revenue by about 37% in the last fiscal year, hauling in more than $1 billion as it prepares to merge with competitor DSM. The Canadian company narrowed its losses in fiscal 2013, down to $35.7 million from $70.7 million the previous year. Private equity owner JLL Partners has struck a deal to merge Patheon with the Netherlands-based DSM later this year, creating a $2-billion-a-year entity that would be the second-largest CMO on the market, the company has said. Results

Editor's Note: An earlier version of this story mis-stated Patheon's year-over-year revenue increase. The correct figure is 36.6%. 

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.